What is the clinical experience with elranatamab for the treatment of MM?

The Multiple Myeloma Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the clinical experience with elranatamab for the treatment of multiple myeloma (MM)?

In this interview, Mohty shared the clinical experience with elranatamab, as well as discussing the mechanism of action of elranatamab, efficacy and safety data from recent trials, and the potential applications for use of elranatamab in combination regimens. Mohty also discussed important considerations for use, including patient selection, management of adverse events, and infection prophylaxis.

Key learnings^1,2

• Elranatamab is a bispecific antibody that targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, enabling T-cell-mediated cytotoxicity of malignant plasma cells.
• In the phase II MagnetisMM-3 trial, the overall response rate observed with elranatamab exceeded 60%. Median progression-free survival was 17.2 months and median overall survival was 24.6 months, indicating promising long-term benefits.
• Ongoing studies are exploring elranatamab in combination with agents such as lenalidomide and carfilzomib.
• Managing adverse events such as cytokine release syndrome, neurotoxicity, and immune effector cell-associated neurotoxicity syndrome is crucial, along with infection management, which includes prophylaxis and early intervention to prevent complications.
• While the safety profile of elranatamab is generally favorable, careful monitoring is required, particularly in patients with higher risk disease or in those who are frail.
• Clinical experience with elranatamab, supported by both clinical trials and real-world data, highlights its potential as an effective treatment for heavily pretreated MM.
• Ongoing studies, particularly in earlier lines of therapy, will offer valuable insights into optimizing its use and addressing unmet needs for MM.

This educational resource is independently supported by Pfizer. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.